SCHEMBL19637169

SCHEMBL19637169

CCc1c(C)nc(OCCN(C)C)nc1N(CC)CCCCO

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22994768 0.84 KDM4E (0.32) —
SCHEMBL22994841 0.84 KDM4E (0.38) —
SCHEMBL19637394 0.77 ABCB11 (0.32) TDP1
SCHEMBL19637079 0.75 HTT (0.32) —
SCHEMBL19637432 0.75 KDM4E (0.36) TDP1
SCHEMBL19637369 0.72 HTT (0.35) —
SCHEMBL21912065 0.71 KDM4E (0.34) —
SCHEMBL25021031 0.68 CRHR1 (0.45) TDP1
SCHEMBL22994752 0.67 KDM4E (0.35) —
SCHEMBL22087278 0.67 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 — — EP disclosed
WO-2020055756-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2020-03-19 — — WO disclosed
WO-2020055760-A1 COMBINATION THERAPIES Mirati Therapeutics, Inc. (US) 2020-03-19 — — WO disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
Send feedback